help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guthrie, G. P.
Right arrow Articles by John, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guthrie, G. P., Jr
Right arrow Articles by John, W. J.

Endocrinology, Vol 107, 1393-1396, Copyright © 1980 by Endocrine Society

ARTICLES

The in vivo glucocorticoid and antiglucocorticoid actions of medroxyprogesterone acetate

GP Guthrie Jr and WJ John

The in vivo glucocorticoid actions of medroxyprogesterone acetate [6 alpha-methyl-17-acetoxy-pregn-4-ene-3,20-dione (MPA)] were assessed in intact prepubertal female Wistar rats using five simultaneous assays: plasma glucose, plasma corticosterone, hepatic glycogen content, hepatic tyrosine aminotransferase activity, and croton oil-induced ear inflammation. Antiglucocorticoid acitivity was measured through interference by MPA with the glucocorticoid effect of a standard 5- microgram dose of dexamethasone in these same assays. The glucocorticoid activity of MPA was evident from suppression of corticosterone and ear inflammation and stimulation of tyrosine aminotransferase activity. The antiglucocorticoid activity of MPA was detected through inhibition of basal and dexamethasone-stimulated hepatic glycogen and partial reversal of the suppression of ear inflammation by dexamethasone. The progestational steroid MPA was thus found to have assay-specific glucocorticoid and antiglucocorticoid actions and may have a potential use in the treatment of some states of glucocorticoid excess.


This article has been cited by other articles:


Home page
 Hum Reprod UpdateHome page
R. Sitruk-Ware
New progestagens for contraceptive use
Hum. Reprod. Update, March 1, 2006; 12(2): 169 - 178.
[Abstract] [Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
A. E. Bonny, J. Ziegler, R. Harvey, S. M. Debanne, M. Secic, and B. A. Cromer
Weight Gain in Obese and Nonobese Adolescent Girls Initiating Depot Medroxyprogesterone, Oral Contraceptive Pills, or No Hormonal Contraceptive Method
Arch Pediatr Adolesc Med, January 1, 2006; 160(1): 40 - 45.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. D. Wagner, M. J. Thomas, J. K. Williams, L. Zhang, K. A. Greaves, and W. T. Cefalu
Insulin Sensitivity and Cardiovascular Risk Factors in Ovariectomized Monkeys with Estradiol Alone or Combined with Nomegestrol Acetate
J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 896 - 901.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1980 by The Endocrine Society